The U.S. FDA approved has given the go-ahead for clinical trials of Cerenis Therapeutics Holding SA's CER-209 drug candidate.
The investigational new drug application for CER-209 involves plans for a phase 1 clinical study in healthy volunteers for the clinical investigation of nonalcoholic fatty liver disease and nonalcoholic steato-hepatitis.
Cerenis intends to start enrollment for the clinical study in the first quarter of 2017.